Palmar plantar erythrodysesthesia risk factors

	Palmar plantar erythrodysesthesia Microchapters
Home
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Palmar plantar erythrodysesthesia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Palmar plantar erythrodysesthesia risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Palmar plantar erythrodysesthesia risk factors
CDC on Palmar plantar erythrodysesthesia risk factors
Palmar plantar erythrodysesthesia risk factors in the news
Blogs on Palmar plantar erythrodysesthesia risk factors
Directions to Hospitals Treating Palmar plantar erythrodysesthesia
Risk calculators and risk factors for Palmar plantar erythrodysesthesia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

The most common and established risk factors are chemotherapeutic agents. The severity of the condition depends on the dose and frequency of the agent.

Exposure to chemotherapeutic agents has been proven to be an established risk factor.
It has a direct relation with the dose of and duration of exposure to chemotherapeutic agents.
The data is limited to support any other associated risk factors as the pathophysiology of palmar plantar erythrodysesthesia.